124 related articles for article (PubMed ID: 26546964)
1. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.
Konner JA; Grabon DM; Gerst SR; Iasonos A; Thaler H; Pezzulli SD; Sabbatini PJ; Bell-McGuinn KM; Tew WP; Hensley ML; Spriggs DR; Aghajanian CA
J Clin Oncol; 2011 Dec; 29(35):4662-8. PubMed ID: 22067389
[TBL] [Abstract][Full Text] [Related]
3. Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.
Tiersten AD; Liu PY; Smith HO; Wilczynski SP; Robinson WR; Markman M; Alberts DS
Gynecol Oncol; 2009 Mar; 112(3):444-9. PubMed ID: 19138791
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
Havrilesky LJ; Secord AA; Darcy KM; Armstrong DK; Kulasingam S;
J Clin Oncol; 2008 Sep; 26(25):4144-50. PubMed ID: 18757328
[TBL] [Abstract][Full Text] [Related]
5. Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer.
Lesnock JL; Farris C; Krivak TC; Smith KJ; Markman M
Gynecol Oncol; 2011 Sep; 122(3):473-8. PubMed ID: 21665250
[TBL] [Abstract][Full Text] [Related]
6. Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study.
Coccolini F; Campanati L; Catena F; Ceni V; Ceresoli M; Jimenez Cruz J; Lotti M; Magnone S; Napoli J; Rossetti D; De Iaco P; Frigerio L; Pinna A; Runnebaum I; Ansaloni L
J Gynecol Oncol; 2015 Jan; 26(1):54-61. PubMed ID: 25376916
[TBL] [Abstract][Full Text] [Related]
7. The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.
Sia TY; Tew WP; Purdy C; Chi DS; Menzin AW; Lovecchio JL; Bookman MA; Cohn DE; Teoh DG; Friedlander M; Bender D; Mutch DG; Gershenson DM; Tewari KS; Wenham RM; Wahner Hendrickson AE; Lee RB; Gray HJ; Secord AA; Van Le L; Lichtman SM
Gynecol Oncol; 2023 Jun; 173():130-137. PubMed ID: 37148580
[TBL] [Abstract][Full Text] [Related]
8. Intraoperative radiotherapy electron boost in advanced and recurrent epithelial ovarian carcinoma: a retrospective study.
Gao Y; Liu Z; Chen X; Luo W; Zhang L; Wang J
BMC Cancer; 2011 Oct; 11():439. PubMed ID: 21989202
[TBL] [Abstract][Full Text] [Related]
9. Doublet chemotherapy in the elderly patient with ovarian cancer.
Teo MY; Power DG; Tew WP; Lichtman SM
Oncologist; 2012; 17(11):1450-60. PubMed ID: 22915061
[TBL] [Abstract][Full Text] [Related]
10. Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.
Sereni MI; Baldelli E; Gambara G; Ravaggi A; Hodge KA; Alberts DS; Guillen-Rodriguez JM; Dong T; Memo M; Odicino F; Angioli R; Liotta LA; Pecorelli SL; Petricoin EF; Pierobon M
Br J Cancer; 2017 Aug; 117(4):494-502. PubMed ID: 28664915
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.
Jaaback K; Johnson N; Lawrie TA
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD005340. PubMed ID: 26755441
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of doublet chemotherapy regimens plus bevacizumab in patients with recurrent ovarian cancer.
Khanmammadov NJ; Doğan İ; Okay NS; Azizy A; Saip P; Aydiner A
Medicine (Baltimore); 2024 Jan; 103(1):e36750. PubMed ID: 38181291
[TBL] [Abstract][Full Text] [Related]
13. Optimal treatment of early-stage ovarian cancer.
Collinson F; Qian W; Fossati R; Lissoni A; Williams C; Parmar M; Ledermann J; Colombo N; Swart A;
Ann Oncol; 2014 Jun; 25(6):1165-71. PubMed ID: 24631948
[TBL] [Abstract][Full Text] [Related]
14. Potential survival benefits from optimized chemotherapy implementation in advanced ovarian cancer: Projections from a microsimulation model.
Lietz AP; Weaver DT; Melamed A; Rauh-Hain JA; Wright JD; Wright AA; Knudsen AB; Pandharipande PV
PLoS One; 2019; 14(9):e0222828. PubMed ID: 31539415
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Efficacy of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel in Improving Survival and Quality of Life in the Advanced Ovarian Cancer Patient Population: A Systematic Review and Meta-Analysis of Randomized Control Trials.
Mansoor M; Shakil F; Jalal U; Shahid F; Jamal M; Ali AS; Abbasi FA; Hijazi H; Imran H; Hirani S; Javaid A; Abu Bakar A; Shah AA; Varrassi G; Khatri M; Kumar S
Cureus; 2023 Dec; 15(12):e51011. PubMed ID: 38264391
[TBL] [Abstract][Full Text] [Related]
16. Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients.
Inciura A; Simavicius A; Juozaityte E; Kurtinaitis J; Nadisauskiene R; Svedas E; Kajenas S
BMC Cancer; 2006 Jun; 6():153. PubMed ID: 16759398
[TBL] [Abstract][Full Text] [Related]
17. Oncological outcomes of intraperitoneal chemotherapy in advanced ovarian cancer: BRCA mutation role.
Padilla-Iserte P; Iváñez M; Muruzabal JC; Navarro R; Díaz-Feijoo B; Iacoponi S; García-Pineda V; Díaz C; Utrilla-Layna J; Gil-Moreno A; Serra A; Gilabert-Estellés J; Martínez Canto C; Tejerizo Á; Lago V; Cárdenas-Rebollo JM; Domingo S;
Eur J Surg Oncol; 2024 Apr; 50(4):108263. PubMed ID: 38492526
[TBL] [Abstract][Full Text] [Related]
18. The Prognostic Value of PARP Expression in High-Grade Epithelial Ovarian Cancer.
Molnár S; Beke L; Méhes G; Póka R
Pathol Oncol Res; 2020 Oct; 26(4):2549-2555. PubMed ID: 32594311
[TBL] [Abstract][Full Text] [Related]
19. Front-line chemo-immunotherapy for treating epithelial ovarian cancer: Part I CA125 and anti-CA125.
Yang ST; Chang WH; Chou FW; Liu HH; Lee WL; Wang PH
Taiwan J Obstet Gynecol; 2023 Nov; 62(6):802-808. PubMed ID: 38008497
[TBL] [Abstract][Full Text] [Related]
20. Role of farletuzumab in epithelial ovarian carcinoma.
Jelovac D; Armstrong DK
Curr Pharm Des; 2012; 18(25):3812-5. PubMed ID: 22591419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
